Thursday
Earnings
FY21 consensus $2.11.…
FY21 consensus $2.11. Raises FY21 revenue view to $2.65B-$2.79B from $2.55B-$2.79B, consensus $2.7B.
Show Hide Related Items >> <<
04/27/21 Endo names Mark Barberio Chairman of Board of Directors 04/13/21 Results in Endo's phase 3 study show meaningful improvement in severe cellulite 04/07/21 Endo comments on default liability judgment in Tennessee State court case 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 04/06/21 RBC Capital Endo transferred with a Sector Perform at RBC Capital 03/08/21 Barclays Endo price target raised to $7 from $6 at Barclays 03/04/21 Citi Endo price target lowered to $10 from $11 at Citi 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 05/06/21 Endo reports Q1 adjusted cont ops EPS 73c, consensus 48c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 04/20/21 California lawyer accuses drugmakers of causing opioid addiction, WSJ reports 02/25/21 Fly Intel: After-Hours Movers 12/18/20 Opening seller repeats Endo straddle sale
Earnings
Reports Q1 revenue…
Reports Q1 revenue $717.92M, consensus $668.65M.
Show Hide Related Items >> <<
04/27/21 Endo names Mark Barberio Chairman of Board of Directors 04/13/21 Results in Endo's phase 3 study show meaningful improvement in severe cellulite 04/07/21 Endo comments on default liability judgment in Tennessee State court case 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 04/06/21 RBC Capital Endo transferred with a Sector Perform at RBC Capital 03/08/21 Barclays Endo price target raised to $7 from $6 at Barclays 03/04/21 Citi Endo price target lowered to $10 from $11 at Citi 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c 04/20/21 California lawyer accuses drugmakers of causing opioid addiction, WSJ reports 02/25/21 Fly Intel: After-Hours Movers 12/18/20 Opening seller repeats Endo straddle sale
Over a week ago
Hot Stocks
Endo International…
Endo International announced that Mark Barberio, who currently serves as an independent member of Endo's Board of Directors, has been appointed Chairman of the Board effective at the company's 2021 Annual General Meeting. Mr. Barberio's appointment is part of Endo's ongoing Board succession process, which has also included adding two new Board members since the company's 2020 Annual General Meeting. In addition, Paul Campanelli, who has served as Chairman of the Board since 2019 and who served as President and CEO from 2016 to 2020, will retire from the Board upon the expiration of his current term at the company's 2021 Annual General Meeting. Finally, Roger Kimmel, who has been Senior Independent Director since 2019 and who served as Chairman of the Board from 2014 to 2019, will also retire from the Board upon the expiration of his current term.
Show Hide Related Items >> <<
04/13/21 Results in Endo's phase 3 study show meaningful improvement in severe cellulite 04/07/21 Endo comments on default liability judgment in Tennessee State court case 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/05/21 Endo subsidiary enters into agreement with Radius Health for abaloparatide 04/06/21 RBC Capital Endo transferred with a Sector Perform at RBC Capital 03/08/21 Barclays Endo price target raised to $7 from $6 at Barclays 03/04/21 Citi Endo price target lowered to $10 from $11 at Citi 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c 04/20/21 California lawyer accuses drugmakers of causing opioid addiction, WSJ reports 02/25/21 Fly Intel: After-Hours Movers 12/18/20 Opening seller repeats Endo straddle sale 11/05/20 Endo options imply 66.9% move in share price post-earnings
Periodicals
A lawyer for several…
A lawyer for several California communities has accused Johnson & Johnson (JNJ), Teva (TEVA), Endo (ENDP), and AbbVie (ABBV) of causing a large wave of opioid addiction due to their aggressive marketing for pain pills, Sara Randazzo of The Wall Street Journal reports. The month long California trial, expected to start in May, could spur drugmakers to finalize settlements, with three large distributors and J&J already having proposed to pay a collective $26B to settle the case. Reference Link
Show Hide Related Items >> <<
04/19/21 Teva announces new data on efficacy of AJOVY 04/08/21 Teva receives EU Marketing Authorization for Seffalair Spiromax 03/31/21 CareDx announces new leadership appointments and promotions 03/08/21 Teva announces launch of generic version of Azopt 1% 04/19/21 J&J says regulatory submissions based on Phase 3 ACIS study won't be pursued 04/19/21 Emergent stops manufacturing at Baltimore facility after FDA inspection 04/16/21 J&J sees no 'causal relationship' between Covid vaccine and blood clots 04/16/21 U.S. exceeds 200M COVID-19 vaccine doses administered 04/13/21 Results in Endo's phase 3 study show meaningful improvement in severe cellulite 04/07/21 Endo comments on default liability judgment in Tennessee State court case 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/05/21 Endo subsidiary enters into agreement with Radius Health for abaloparatide 04/07/21 AbbVie submits regulatory applications for SKYRIZI to FDA, EMA 04/04/21 AbbVie announces extension of review of sNDA of upadacitinib 04/01/21 AbbVie: NEJM publishes 24-week results from Phase 3 RINVOQ study 03/30/21 AbbVie: FDA accepts NDA for atogepant 04/19/21 Chardan Chardan sees J&J moving forward with Emergent if observations are minor 04/14/21 Guggenheim Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim 04/13/21 Goldman Sachs J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs 04/13/21 Morgan Stanley Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers 04/06/21 RBC Capital Teva transferred with a Sector Perform at RBC Capital 01/26/21 Piper Sandler Amarin in 'strong position' against Health Net, says Piper Sandler 12/21/20 Gabelli Teva named 'Best Idea for 2021' at Gabelli 11/27/20 H.C. Wainwright Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright 04/06/21 RBC Capital Endo transferred with a Sector Perform at RBC Capital 03/08/21 Barclays Endo price target raised to $7 from $6 at Barclays 03/04/21 Citi Endo price target lowered to $10 from $11 at Citi 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 04/06/21 RBC Capital AbbVie transferred with an Outperform at RBC Capital 04/01/21 Piper Sandler Integra to benefit from FDA safety communication, says Piper Sandler 04/01/21 Piper Sandler Piper migraine survey bearish for Amgen, bullish for Biohaven 03/17/21 JPMorgan AbbVie selloff on Rinvoq deal 'appears overdone,' says JPMorgan 02/10/21 Teva sees Q1 lowest for EPS, sales in FY21 02/10/21 Teva sees FY21 EBITDA $4.8B-$5.1B 02/10/21 Teva sees FY21 EPS $2.50-$2.70, consensus $2.63 02/10/21 Teva reports Q4 EPS 68c, consensus 63c 04/19/21 Notable companies reporting before tomorrow's open 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c 02/03/21 AbbVie sees FY21 adjusted EPS $12.32-$12.52, consensus $12.18 02/03/21 AbbVie reports Q4 adjusted EPS $2.92, consensus $2.85 02/02/21 Notable companies reporting before tomorrow's open 03/17/21 Biogen, Alkermes sue Teva to block MS drug, Bloomberg reports 02/10/21 CEO says Teva in discussions to co-produce COVID vaccine, Reuters reports 02/09/21 Teva wins new hearing on $235M GSK patent verdict, Bloomberg reports 11/13/20 Teva facing EU antitrust investigation over Copaxone sales, Bloomberg reports 04/19/21 J&J affirms 100M vaccine commitment in U.S. to CNBC 04/19/21 J&J COVID-19 vaccine paused, concerns of mistreating blood clots, WSJ reports 04/18/21 Fauci predicts resumption of J&J COVID vaccine use, Reuters reports 04/16/21 J&J reached out to vaccine rivals to study blood clot risk, WSJ reports 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 03/15/21 AbbVie in discussions to sell $5B women's drug portfolio, Reuters reports 12/16/20 AbbVie unit wins ITC trade secret case against Evolus, Bloomberg says 12/16/20 AbbVie unit wins ITC trade secret case against Evolus, Bloomberg says 12/09/20 Former Allergan CEO's SPAC to merge with HydraFacial Co, WSJ reports 02/10/21 Fly Intel: Wall Street's top stories for Wednesday 02/10/21 Fly Intel: Wall Street's top stories at midday 11/19/20 Fly Intel: Wall Street's top stories for Thursday 11/19/20 Fly Intel: Wall Street's top stories at midday 04/16/21 Fly Intel: Wall Street's top stories for Friday 04/16/21 Fly Intel: Wall Street's top stories at midday 04/13/21 Fly Intel: Wall Street's top stories for Tuesday 04/13/21 Fly Intel: Wall Street's top stories at midday 02/25/21 Fly Intel: After-Hours Movers 02/19/21 Fly Intel: Wall Street's top stories for Friday 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 02/02/21 Teva call volume above normal and directionally bullish 01/19/21 Teva call volume above normal and directionally bullish 01/06/21 Notable open interest changes for January 6th 01/04/21 Teva call volume above normal and directionally bullish 04/13/21 Unusually active option classes on open April 13th 04/01/21 Unusually active option classes on open April 1st 03/01/21 Unusually active option classes on open March 1st 01/26/21 Early notable gainers among liquid option names on January 26th 12/18/20 Opening seller repeats Endo straddle sale 11/05/20 Endo options imply 66.9% move in share price post-earnings 03/17/21 Unusually active option classes on open March 17th 02/05/21 Unusually active option classes on open February 5th 01/27/21 AbbVie put volume heavy and directionally bearish 11/10/20 AbbVie call volume above normal and directionally bullish
Hot Stocks
The company states:…
The company states: "Endo International announced that Phase 3 data evaluating Qwo, or collagenase clostridium histolyticum-aaes for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery. In addition to Phase 3 studies, the publication also includes a supplemental video that demonstrates the injection techniques for QWO. The Phase 3 studies, conducted from February 2018 to September 2018, demonstrated that QWO provides a clinically meaningful improvement in the appearance of moderate to severe cellulite in the buttocks of adult women compared to placebo. QWO received FDA approval in July 2020 and is the first and only injectable treatment for moderate to severe cellulite in the buttocks of adult women."
Show Hide Related Items >> <<
04/07/21 Endo comments on default liability judgment in Tennessee State court case 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/05/21 Endo subsidiary enters into agreement with Radius Health for abaloparatide 01/05/21 Radius Health enters commercial agreement with Paladin Labs for abaloparatide 04/06/21 RBC Capital Endo transferred with a Sector Perform at RBC Capital 03/08/21 Barclays Endo price target raised to $7 from $6 at Barclays 03/04/21 Citi Endo price target lowered to $10 from $11 at Citi 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 02/25/21 Fly Intel: After-Hours Movers 10/19/20 Fly Intel: Wall Street's top stories for Monday 10/19/20 Fly Intel: Wall Street's top stories at midday 12/18/20 Opening seller repeats Endo straddle sale 11/05/20 Endo options imply 66.9% move in share price post-earnings
Over a month ago
Hot Stocks
Endo announced the entry…
Endo announced the entry of an order granting a default judgment on liability against its wholly-owned subsidiaries Endo Health Solutions and Endo Pharmaceuticals in Staubus, et al. v. Purdue Pharma, L.P., et al., which has been pending in the Circuit Court at Kingsport, Tennessee since 2017. The Staubus case involves allegations by three Tennessee District Attorneys General and an individual plaintiff that EHSI's and EPI's sale of prescription opioid medications violated Tennessee's Drug Dealer Liability Act. In December, the Tennessee Supreme Court unanimously ruled that Tennessee's District Attorneys General do not have standing to bring claims under the DDLA. On April 5, the Staubus court permitted several Tennessee counties to substitute into the case in place of the District Attorney General plaintiffs. On April 6, the Staubus court entered a default judgment against Endo on liability as a sanction for alleged discovery improprieties. The order does not address the issue of damages, which the Staubus court ordered to be tried at a future date. Endo has made efforts to address the Staubus court's concerns, including by hiring an additional law firm, producing additional documents and offering additional depositions at Endo's expense. Endo "strongly disagrees" with the Staubus court's orders and will seek review of the Staubus court's orders by the Tennessee appellate courts.
Show Hide Related Items >> <<
02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/05/21 Endo subsidiary enters into agreement with Radius Health for abaloparatide 01/05/21 Radius Health enters commercial agreement with Paladin Labs for abaloparatide 01/04/21 Endo: Par Pharmaceutical begins shipping generic version of Amitiza 04/06/21 RBC Capital Endo transferred with a Sector Perform at RBC Capital 03/08/21 Barclays Endo price target raised to $7 from $6 at Barclays 03/04/21 Citi Endo price target lowered to $10 from $11 at Citi 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 02/25/21 Fly Intel: After-Hours Movers 10/19/20 Fly Intel: Wall Street's top stories for Monday 10/19/20 Fly Intel: Wall Street's top stories at midday 12/18/20 Opening seller repeats Endo straddle sale 11/05/20 Endo options imply 66.9% move in share price post-earnings
Recommendations
RBC Capital transferred…
RBC Capital transferred coverage of Endo to analyst Daniel Busby, and kept a Sector Perform rating and $7 price target on the stock.
Show Hide Related Items >> <<
02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/05/21 Endo subsidiary enters into agreement with Radius Health for abaloparatide 01/05/21 Radius Health enters commercial agreement with Paladin Labs for abaloparatide 01/04/21 Endo: Par Pharmaceutical begins shipping generic version of Amitiza 03/08/21 Barclays Endo price target raised to $7 from $6 at Barclays 03/04/21 Citi Endo price target lowered to $10 from $11 at Citi 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 01/04/21 Piper Sandler Endo price target raised to $12 from $6 at Piper Sandler 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 02/25/21 Fly Intel: After-Hours Movers 10/19/20 Fly Intel: Wall Street's top stories for Monday 10/19/20 Fly Intel: Wall Street's top stories at midday 12/18/20 Opening seller repeats Endo straddle sale 11/05/20 Endo options imply 66.9% move in share price post-earnings
Recommendations
Barclays analyst Balaji…
Barclays analyst Balaji Prasad raised the firm's price target on Endo to $7 from $6 and keeps an Equal Weight rating on the shares. After holding an expert panel with two dermatologists to discuss the cellulite treatment landscape and potential for Endo's Qwo, the analyst is positive on the upcoming launch. The experts noted optimal Qwo pricing was very important for uptake, as consumers were unlikely to spend thousands of dollars on cellulite treatment, Prasad tells investors in a research note.
Show Hide Related Items >> <<
02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/05/21 Endo subsidiary enters into agreement with Radius Health for abaloparatide 01/05/21 Radius Health enters commercial agreement with Paladin Labs for abaloparatide 01/04/21 Endo: Par Pharmaceutical begins shipping generic version of Amitiza 03/04/21 Citi Endo price target lowered to $10 from $11 at Citi 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 01/04/21 Piper Sandler Endo price target raised to $12 from $6 at Piper Sandler 11/23/20 Citi Citi recommends pair trade of overweight Endo, underweight Teva 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 02/25/21 Fly Intel: After-Hours Movers 10/19/20 Fly Intel: Wall Street's top stories for Monday 10/19/20 Fly Intel: Wall Street's top stories at midday 09/25/20 Fly Intel: Pre-market Movers 12/18/20 Opening seller repeats Endo straddle sale 11/05/20 Endo options imply 66.9% move in share price post-earnings
Recommendations
Citi analyst Navann Ty…
Citi analyst Navann Ty lowered the firm's price target on Endo to $10 from $11 and keeps a Buy rating on the shares. The stock dropped significantly after releasing "strong" fiscal 2020 earnings, driven by a lower than expected 2021 outlook, Ty tells investors in a research note. The analyst sill has a positive view of Qwo and Biospecifics, potential for a lower than expected opioid settlement and Novavax upside.
Show Hide Related Items >> <<
02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/05/21 Endo subsidiary enters into agreement with Radius Health for abaloparatide 01/05/21 Radius Health enters commercial agreement with Paladin Labs for abaloparatide 01/04/21 Endo: Par Pharmaceutical begins shipping generic version of Amitiza 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 01/04/21 Piper Sandler Endo price target raised to $12 from $6 at Piper Sandler 11/23/20 Citi Citi recommends pair trade of overweight Endo, underweight Teva 10/20/20 H.C. Wainwright BioSpecifics downgraded to Neutral from Buy at H.C. Wainwright 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 02/25/21 Fly Intel: After-Hours Movers 10/19/20 Fly Intel: Wall Street's top stories for Monday 10/19/20 Fly Intel: Wall Street's top stories at midday 09/25/20 Fly Intel: Pre-market Movers 12/18/20 Opening seller repeats Endo straddle sale 11/05/20 Endo options imply 66.9% move in share price post-earnings
Conference/Events
Global High Yield &…
Global High Yield & Leveraged Finance Virtual Conference will be held on March 1-3.
Show Hide Related Items >> <<
02/03/21 TTM Technologies announces $100M repurchase pact 02/11/21 ARC Resources, Seven Generations announce strategic combination 02/17/21 SM Energy sees 2021 production 47-50 MMBoe 01/13/21 SM Energy falls -9.3% 12/21/20 SM Energy falls -10.7% 10/30/20 SM Energy promotes Herbert Vogel to CEO 02/18/21 Mednax falls -23.9% 02/18/21 Mednax falls -19.3% 02/18/21 Mednax falls -15.9% 01/19/21 Surgical Directions announces management buyout deal with Mednax 02/09/21 Gartner raises share repurchase authorization by $300M 02/09/21 Gartner CEO says 'well-positioned for 2021' 11/18/20 Gartner director sells 7.1K shares of common stock 11/12/20 Gartner CEO sells 35.9K shares of common stock 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 01/05/21 Endo subsidiary enters into agreement with Radius Health for abaloparatide 01/05/21 Radius Health enters commercial agreement with Paladin Labs for abaloparatide 01/04/21 Endo: Par Pharmaceutical begins shipping generic version of Amitiza EBS Emergent BioSolutions 02/19/21 Emergent BioSolutions falls -8.8% 02/19/21 Emergent BioSolutions falls -7.8% 02/19/21 Emergent BioSolutions falls -9.9% 02/03/21 Emergent intranasal influenza vaccine shows 'strong response' in Phase 1 study CENT Central Garden & Pet 12/31/20 Central Garden & Pet signs agreement to acquire Green Garden Products for $532M 12/17/20 Central Garden & Pet to acquire Hopewell Nursery 11/13/20 Beazer Homes falls -6.0% 11/12/20 Beazer Homes reports Q4 homebuilding revenue down 12.2% at $679.1M 09/22/20 Beazer Homes says net new orders for Q4 up 37% y/y 12/17/20 ASGN unit awarded $28.8M USMC IT service and support contract 12/01/20 ASGN acquires Integrated Solutions Management 10/01/20 ASGN acquires Skyris, terms not disclosed 02/11/21 Truist ASGN price target raised to $108 from $80 at Truist 11/23/20 BMO Capital ASGN price target raised to $93 from $88 at BMO Capital 07/31/20 Truist ASGN price target raised to $80 from $72 at SunTrust 07/30/20 Credit Suisse ASGN price target raised to $60 from $50 at Credit Suisse EBS Emergent BioSolutions 02/24/21 Chardan Chardan reverses last week's downgrade, upgrades Emergent to Buy 02/24/21 Chardan Emergent BioSolutions upgraded to Buy from Neutral at Chardan 02/19/21 Fly Intel: Top five analyst downgrades 02/19/21 Chardan Emergent BioSolutions downgraded to Neutral from Buy at Chardan 02/26/21 Wells Fargo Crestwood Equity upgraded at Wells Fargo on 'solid' 2021 outlook 02/26/21 Wells Fargo Crestwood Equity upgraded to Equal Weight from Underweight at Wells Fargo 02/16/21 Truist Crestwood Equity upgraded to Buy from Hold at Truist 02/16/21 Truist Crestwood Equity upgraded to Buy from Hold at Truist 02/04/21 B. Riley TTM Technologies price target raised to $19.25 from $17.75 at B. Riley Securities 01/15/21 Truist TTM Technologies price target raised to $16 from $15 at Truist 09/29/20 Craig-Hallum Craig-Hallum bullish on TTM Technologies, initiates with a Buy 09/29/20 Craig-Hallum TTM Technologies initiated with a Buy at Craig-Hallum 02/22/21 RBC Capital SM Energy price target raised to $18 from $12 at RBC Capital 02/03/21 JPMorgan SM Energy upgraded to Neutral with $13 target at JPMorgan 02/03/21 JPMorgan SM Energy upgraded to Neutral from Underweight at JPMorgan 01/14/21 Barclays SM Energy downgraded to Underweight from Equal Weight at Barclays 02/19/21 National Bank Seven Generations price target raised to C$14 from C$10 at National Bank 02/12/21 National Bank Seven Generations downgraded to Tender from Outperform at National Bank 02/12/21 BMO Capital Seven Generations downgraded to Market Perform from Outperform at BMO Capital 02/12/21 Stifel ARC Resources price target raised to C$12.25 from C$10.75 at Stifel 12/08/20 JPMorgan Telenet upgraded to Overweight from Neutral at JPMorgan 11/04/20 UBS Telenet price target lowered to EUR 33 from EUR 41.50 at UBS 10/23/20 Barclays Telenet price target raised to EUR 43 from EUR 40 at Barclays 10/15/20 BofA Telenet upgraded to Buy from Underperform at BofA 01/19/21 Citi Endo price target raised to $9 from $7 at Citi 01/04/21 Piper Sandler Endo price target raised to $12 from $6 at Piper Sandler 11/23/20 Citi Citi recommends pair trade of overweight Endo, underweight Teva 10/20/20 H.C. Wainwright BioSpecifics downgraded to Neutral from Buy at H.C. Wainwright 02/19/21 Deutsche Bank Mednax price target raised to $17.50 from $14 at Deutsche Bank 02/19/21 Citi Mednax price target lowered to $22 from $24 at Citi 01/05/21 Truist Mednax price target raised to $26 from $20 at Truist 10/19/20 Fly Intel: Top five analyst downgrades 12/11/20 Sidoti Beazer Homes initiated with a Buy at Sidoti 04/07/20 Wedbush Beazer Homes price target lowered to $8 from $16 at Wedbush CENT Central Garden & Pet 02/04/21 Truist Central Garden & Pet price target raised to $45 from $40 at Truist 05/14/20 Truist Scotts Miracle-Gro, Central Garden & Pet price targets raised at SunTrust 03/18/20 BofA Central Garden & Pet upgraded to Buy from Neutral at BofA 03/18/20 BofA Central Garden & Pet upgraded to Buy from Neutral at BofA 02/10/21 Wells Fargo Gartner price target raised to $187 from $145 at Wells Fargo 02/10/21 Barclays Gartner price target raised to $185 from $134 at Barclays 01/13/21 KeyBanc Windows upside could be limited with growth skewed to consumer, says KeyBanc 01/06/21 Morgan Stanley Gartner upgraded to Overweight from Equal Weight at Morgan Stanley 02/03/21 TTM Technologies sees Q1 EPS 19c-25c, consensus 24c 02/03/21 TTM Technologies reports Q4 EPS 35c, consensus 25c 10/28/20 TTM Technologies sees Q4 EPS 22c-28c, consensus 24c 10/28/20 TTM Technologies reports Q3 EPS 25c, consensus 19c 02/17/21 SM Energy reports Q4 adjusted EPS 2c, consensus 5c 02/17/21 SM Energy reports Q4 adjusted EPS 2c, consensus 5c 10/29/20 SM Energy reports Q3 EPS (86c), consensus (28c) 02/18/21 Mednax reports Q4 non-GAAP EPS 25c, consensus 36c 11/06/20 Mednax reports Q3 adjusted EPS 37c, consensus 40c 02/09/21 Gartner reports Q4 adjusted EPS $1.59, consensus 82c 11/03/20 Gartner raises FY20 adj. EPS to 'at least' $4.07 from $3.08, consensus $3.17 11/03/20 Gartner reports Q3 adjusted EPS 91c, consensus 52c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees Q1 adjusted EPS 40c-50c, consensus 53c 02/25/21 Endo sees FY21 adjusted EPS $1.80-$2.30, consensus $2.32 02/25/21 Endo reports Q4 adjusted EPS 75c, consensus 48c EBS Emergent BioSolutions 02/18/21 Emergent BioSolutions sees FY21 revenue $1.95B-$2.05B, consensus $1.93B 02/18/21 Emergent BioSolutions reports Q4 adjusted EPS $3.67, consensus $3.19 01/10/21 Emergent BioSolutions sees FY20 revenue $1.55B-$1.56B, consensus $1.53B 11/05/20 Emergent BioSolutions sees FY20 revenue $1.52B-$1.58B, consensus $1.53B 02/23/21 Crestwood Equity reports Q4 EPS 3c, consensus 31c 10/27/20 Crestwood Equity sees Q4 revenue to exceed midpoint of $520M-$570M 10/27/20 Crestwood Equity reports Q3 EPS (28c), consensus (6c) 01/28/21 Beazer Homes reports Q1 EPS 40c, consensus 29c 11/12/20 Beazer Homes reports Q4 EPS 82c vs. 8c last year 02/10/21 ASGN sees Q1 adjusted EPS $1.05-$1.12, consensus $1.02 02/10/21 ASGN reports Q4 adjusted EPS $1.31, consensus $1.15 10/28/20 ASGN sees Q4 adjusted EPS $1.09-$1.16, consensus $1.06 10/28/20 ASGN reports Q3 adjusted EPS $1.27, consensus $1.11 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports EBS Emergent BioSolutions 11/12/20 Emergent BioSolutions off lows after 60 Minutes Overtime tours facility 02/03/21 Fly Intel: After-Hours Movers 02/18/21 Fly Intel: Wall Street's top stories for Thursday 02/18/21 Fly Intel: Wall Street's top stories at midday 02/25/21 Fly Intel: After-Hours Movers 10/19/20 Fly Intel: Wall Street's top stories for Monday 10/19/20 Fly Intel: Wall Street's top stories at midday 09/25/20 Fly Intel: Pre-market Movers 01/28/21 Fly Intel: After-Hours Movers 11/12/20 Fly Intel: After-Hours Movers 02/09/21 Early notable gainers among liquid option names on February 9th 12/18/20 Opening seller repeats Endo straddle sale 11/05/20 Endo options imply 66.9% move in share price post-earnings